We carried out a prospective study at the Peking Union Medical College Hospital (PUMCH) in Beijing, China, between July 2019 and December 2019.
In accordance with the patients’ presentations and the outcomes of auxiliary tests, patients underwent normal diagnostic workups. Including criteria for allergy patients (Simon, 2019 (link)): diagnosed with allergy diseases by clinical doctors, including allergic rhinitis, asthma, urticaria, atopic dermatitis, cough, atopic conjunctivitis, eczema, or a history of severe anaphylactic reaction (Eigenmann, 2005 (link)); positive serum specific IgE, positive skin prick test or intradermal test. Excluding criteria for allergy patients (Simon, 2019 (link)): patients with serious other diseases, such as diabetes, liver disease, kidney disease, etc., (Eigenmann, 2005 (link)); Immunocompromised patients.
Including criteria for healthy participants (Simon, 2019 (link)): No symptoms of any allergic diseases, including allergic rhinitis, allergic asthma, atopic dermatitis, allergic conjunctivitis, etc., (Eigenmann, 2005 (link)) No history of allergic diseases, family history (Han et al., 2020 (link)). No other immune system diseases (Bønnelykke et al., 2015 (link)). No organic disease (Tamari and Hirota, 2014 (link)). Voluntary acceptance of disease-related questionnaires (Haider et al., 2022 (link)). No participation in any drug clinical trials within 3 months. Excluding criteria for healthy participants (Simon, 2019 (link)): history of allergic diseases or chronic medical conditions associated with allergy diseases in this study (Eigenmann, 2005 (link)); history of significant allergen exposure (Han et al., 2020 (link)); patients with serious other diseases, such as diabetes, liver disease, kidney disease, etc., (Bønnelykke et al., 2015 (link)); Immunocompromised patients.
In accordance with the patients’ presentations and the outcomes of auxiliary tests, patients underwent normal diagnostic workups. Including criteria for allergy patients (Simon, 2019 (link)): diagnosed with allergy diseases by clinical doctors, including allergic rhinitis, asthma, urticaria, atopic dermatitis, cough, atopic conjunctivitis, eczema, or a history of severe anaphylactic reaction (Eigenmann, 2005 (link)); positive serum specific IgE, positive skin prick test or intradermal test. Excluding criteria for allergy patients (Simon, 2019 (link)): patients with serious other diseases, such as diabetes, liver disease, kidney disease, etc., (Eigenmann, 2005 (link)); Immunocompromised patients.
Including criteria for healthy participants (Simon, 2019 (link)): No symptoms of any allergic diseases, including allergic rhinitis, allergic asthma, atopic dermatitis, allergic conjunctivitis, etc., (Eigenmann, 2005 (link)) No history of allergic diseases, family history (Han et al., 2020 (link)). No other immune system diseases (Bønnelykke et al., 2015 (link)). No organic disease (Tamari and Hirota, 2014 (link)). Voluntary acceptance of disease-related questionnaires (Haider et al., 2022 (link)). No participation in any drug clinical trials within 3 months. Excluding criteria for healthy participants (Simon, 2019 (link)): history of allergic diseases or chronic medical conditions associated with allergy diseases in this study (Eigenmann, 2005 (link)); history of significant allergen exposure (Han et al., 2020 (link)); patients with serious other diseases, such as diabetes, liver disease, kidney disease, etc., (Bønnelykke et al., 2015 (link)); Immunocompromised patients.
Free full text: Click here
